Compare IMMP & WBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | WBX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Australia | Spain |
| Employees | N/A | 696 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 53.4M |
| IPO Year | 2012 | N/A |
| Metric | IMMP | WBX |
|---|---|---|
| Price | $0.37 | $3.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $5.50 | $4.75 |
| AVG Volume (30 Days) | ★ 634.9K | 101.6K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $445.09 | $18.10 |
| Revenue Next Year | N/A | $94.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.29 |
| 52 Week High | $3.53 | $7.83 |
| Indicator | IMMP | WBX |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 65.63 |
| Support Level | $0.35 | $2.50 |
| Resistance Level | $0.39 | $3.97 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 33.66 | 79.30 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.